BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 20946166)

  • 1. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
    Hillarp A; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Lindahl TL
    J Thromb Haemost; 2011 Jan; 9(1):133-9. PubMed ID: 20946166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
    Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jochmans K; Mullier F; Wijns W; Soumali MR; Coucke W; Vernelen K; Van de Walle P
    Thromb Haemost; 2015 Jan; 113(1):154-64. PubMed ID: 25231101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
    Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
    Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays.
    Hillarp A; Gustafsson KM; Faxälv L; Strandberg K; Baghaei F; Fagerberg Blixter I; Berndtsson M; Lindahl TL
    J Thromb Haemost; 2014 Sep; 12(9):1545-53. PubMed ID: 24965851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time.
    Mani H; Hesse C; Stratmann G; Lindhoff-Last E
    Thromb Haemost; 2011 Jul; 106(1):156-64. PubMed ID: 21655672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents.
    Dale BJ; Ginsberg JS; Johnston M; Hirsh J; Weitz JI; Eikelboom JW
    J Thromb Haemost; 2014 Nov; 12(11):1810-5. PubMed ID: 25196577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
    Hillarp A; Strandberg K; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Lindahl TL
    Scand J Clin Lab Invest; 2018; 78(7-8):575-583. PubMed ID: 30278787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
    Gosselin RC; Adcock D; Hawes EM; Francart SJ; Grant RP; Moll S
    Thromb Haemost; 2015 Jan; 113(1):77-84. PubMed ID: 25413383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.
    Douxfils J; Mullier F; Loosen C; Chatelain C; Chatelain B; Dogné JM
    Thromb Res; 2012 Dec; 130(6):956-66. PubMed ID: 23006523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
    Schmitz EM; Boonen K; van den Heuvel DJ; van Dongen JL; Schellings MW; Emmen JM; van der Graaf F; Brunsveld L; van de Kerkhof D
    J Thromb Haemost; 2014 Oct; 12(10):1636-46. PubMed ID: 25142183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.
    Helin TA; Pakkanen A; Lassila R; Joutsi-Korhonen L
    Clin Chem; 2013 May; 59(5):807-14. PubMed ID: 23378569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
    Cuker A; Siegal DM; Crowther MA; Garcia DA
    J Am Coll Cardiol; 2014 Sep; 64(11):1128-39. PubMed ID: 25212648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
    Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
    J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
    Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR
    Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions.
    Mani H; Hesse C; Stratmann G; Lindhoff-Last E
    Thromb Haemost; 2013 Jan; 109(1):127-36. PubMed ID: 23138190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation.
    Molenaar PJ; Dinkelaar J; Leyte A
    Clin Chem Lab Med; 2012 Oct; 50(10):1799-807. PubMed ID: 23089710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assays for measuring rivaroxaban: their suitability and limitations.
    Lindhoff-Last E; Samama MM; Ortel TL; Weitz JI; Spiro TE
    Ther Drug Monit; 2010 Dec; 32(6):673-9. PubMed ID: 20844464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.